Genzyme, a Sanofi company, announced today that the Nova Scotia Drug Program has included Aubagio (teriflunomide) 14 mg on the provincial drug formulary as a first-line oral agent for people in the province living with relapsing-remitting multiple sclerosis (RRMS). 

Aubagio is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

Dr. Virender Bhan, Director, Dalhousie MS Research Unit, states: "I am pleased that Aubagio has gained a listing in Nova Scotia. This recently approved oral medication provides another reasonably safe and effective treatment choice for our MS patients."

"The MS Society is pleased that the Province of Nova Scotia remains responsive with their coverage of new treatments, including oral therapies, for those living with multiple sclerosis," says Dena Simon, President, Atlantic Division, MS Society of Canada. "This responsiveness means Nova Scotians living with MS have greater access and more choice when it comes to treatments that manage the effects of their disease. For people with MS who are interested in exploring treatment options, we encourage them to consult with their healthcare team to find the course that is most appropriate for them."

For more details, go to: https://ca.finance.yahoo.com/news/nova-scotia-funds-treatment-aubagio-164000212.html